Fjarde AP Fonden Fourth Swedish National Pension Fund Makes New Investment in Pulmonx Corporation $LUNG

Fjarde AP Fonden Fourth Swedish National Pension Fund purchased a new position in shares of Pulmonx Corporation (NASDAQ:LUNG) during the second quarter, Holdings Channel reports. The firm purchased 76,253 shares of the company’s stock, valued at approximately $197,000.

A number of other hedge funds also recently bought and sold shares of the business. Deutsche Bank AG boosted its position in Pulmonx by 4.2% during the first quarter. Deutsche Bank AG now owns 1,147,105 shares of the company’s stock worth $7,720,000 after purchasing an additional 46,116 shares in the last quarter. Parkman Healthcare Partners LLC boosted its position in Pulmonx by 194.4% during the first quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company’s stock worth $4,118,000 after purchasing an additional 404,022 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in Pulmonx by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 320,946 shares of the company’s stock worth $2,160,000 after purchasing an additional 5,414 shares in the last quarter. Essex Investment Management Co. LLC purchased a new position in Pulmonx during the first quarter worth approximately $2,041,000. Finally, Trexquant Investment LP boosted its position in Pulmonx by 140.0% during the first quarter. Trexquant Investment LP now owns 224,909 shares of the company’s stock worth $1,514,000 after purchasing an additional 131,209 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company’s stock.

Pulmonx Price Performance

NASDAQ:LUNG opened at $2.00 on Friday. Pulmonx Corporation has a one year low of $1.47 and a one year high of $9.37. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.63 and a current ratio of 5.35. The stock has a market cap of $81.50 million, a PE ratio of -1.40 and a beta of 0.42. The stock has a 50 day moving average price of $1.70 and a 200 day moving average price of $2.58.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.02. Pulmonx had a negative return on equity of 69.76% and a negative net margin of 62.88%.The firm had revenue of $23.86 million during the quarter, compared to analysts’ expectations of $23.46 million. Equities research analysts expect that Pulmonx Corporation will post -1.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LUNG has been the topic of several research reports. Stifel Nicolaus decreased their target price on Pulmonx from $16.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, July 31st. Wall Street Zen downgraded Pulmonx from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Pulmonx in a research report on Wednesday, October 8th. Wells Fargo & Company decreased their target price on Pulmonx from $6.00 to $3.00 and set an “equal weight” rating on the stock in a research report on Friday, August 1st. Finally, D. Boral Capital decreased their target price on Pulmonx from $16.00 to $14.00 and set a “buy” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $6.81.

Pulmonx Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.